Cold, Flu & Cough News and Research

Latest Cold, Flu & Cough News and Research

First nationwide human immunology registry for infectious disease research

RemedyMD (www.RemedyMD.com), the leading provider of disease registry software, today announced the first nationwide human immunology registry for infectious disease research. The new registry was developed to help clinicians and researchers better understand the human immune response to emerging and re-emerging infectious diseases.

21 Nov 2009

UNICEF report highlights gains in child health, while 1b still lack essential services

A special edition of UNICEF's annual State of the World's Children report, released 20 years after the U.N. Convention on the Rights of the Child, shows that "fewer youngsters are dying and more are going to school - but an estimated 1 billion still lack services essential to their survival and development," the Associated Press reports.

20 Nov 2009

FDA approves sNDA for pediatric autism drug ABILIFY

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for ABILIFY® (aripiprazole) for the treatment of irritability associated with autistic disorder in pediatric patients ages 6 to 17 years, including symptoms of aggression towards others, deliberate self-injuriousness, temper tantrums, and quickly changing moods.

20 Nov 2009

Study recommends chest ultrasound for evaluating pediatric patients with complicated pneumonia

Chest ultrasound can serve as a viable alternative to chest CT in the evaluation of pediatric patients with complicated pneumonia and parapneumonic effusion (a build-up of fluid between the lung and chest wall), according to a study published in the December issue of the American Journal of Roentgenology.

20 Nov 2009

Evidence does not connect H1N1 vaccine to patient deaths, WHO says

The deaths of 41 people from six countries who had received the H1N1 (swine flu) vaccine were not directly linked to the vaccine, the WHO said Thursday, the Associated Press/MSNBC reports (11/19).

20 Nov 2009

Inovio Biomedical announces positive test results of its consensus influenza vaccines

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today that a combination of its synthetic consensus H1N1, H2N2, H3N2, and H5N1 influenza vaccine candidates achieved protective antibody responses against several different influenza sub-types and strains in ferrets.

20 Nov 2009

Only 1 in 4 Americans aged 50-64 regularly take advantage of preventive screenings, says report

Only about 1 in 4 Americans aged 50-64 regularly take advantage of preventive services such as screenings and immunizations, according to a report from the Centers for Disease Control and Prevention in collaboration with AARP and the American Medical Association (AMA).

20 Nov 2009

LAIV and TIV vaccines appear to offer protection against A/H1N1 virus

Immunization with either live attenuated influenza vaccine (LAIV, also known as FluMist®), or trivalent inactivated influenza vaccine (TIV), appears to offer a protection (~ 45%) against the novel A/H1N1 virus, the cause of the present influenza pandemic. However, the benefit was largely attributed to the youngest age group. The finding emerges from an evaluation of medical encounters and seasonal influenza immunization of U.S. military service members.

20 Nov 2009

"EurSafety Health-net" launched to fight hospital acquired MRSA infection

On November 19, 2009, the kick-off meeting for the Euregio-project "EurSafety Health-net" has taken place. EurSafety Health-net is the follow-up of EUREGIO MRSA-net, that, according to the Robert Koch Institute, gained some sort of model character all over the nation when talking about prevention of hospital acquired MRSA infection. Besides the protection against infection, the main goal of this new project is to strengthen the patients' safety on both sides of the border.

20 Nov 2009

Leading driver of antibiotic selection in nosocomial pneumonia in Europe found

Arlington Medical Resources (AMR) and Decision Resources find that the leading driver of antibiotic selection in nosocomial pneumonia in Europe is broad-spectrum activity against gram-positive and gram-negative pathogens.

20 Nov 2009

WSNA highlights serious concerns about safety of nurses and patients during H1N1 pandemic

Washington State Nurses Association (WSNA), representing more than 1,600 registered nurses at Sacred Heart Medical Center, is holding a press conference today to highlight serious concerns about the safety of nurses and patients at Sacred Heart Medical Center during this H1N1 pandemic.

20 Nov 2009

H1N1: Bridging the knowledge gap

A commentary in the December issue of The Lancet Infectious Diseases brings to light the gaps in knowledge on the transmission of a common pathogen - the influenza virus - and its impact on decisions about how best to protect health care workers. Infectious diseases specialist Leonard Mermel, DO, medical director of infection control for Rhode Island Hospital, looks at the ongoing debate in light of the H1N1 pandemic, what past research tells us about the spread of influenza, and what is missing in the debate. His commentary is currently available in an online first edition.

20 Nov 2009

BioCryst Pharmaceuticals declares proposed public offering of common stock

BioCryst Pharmaceuticals, Inc. today announced the pricing of a public offering of 5,000,000 shares of its common stock at $9.75 per share, resulting in gross proceeds of $48.75 million.

19 Nov 2009

High prevalence of asthma among children with H1N1

A new study on pediatric H1N1 influenza admissions has found that asthma is a significant risk factor for severe disease in children with pandemic H1N1 compared with the seasonal flu.

19 Nov 2009

Low-level laser therapy increases tumour growth in skin cancer

High irradiances of low-level laser therapy (LLLT) should not be used over melanomas. Researchers writing in the open access journal BMC Cancer studied the pain relieving, anti-inflammatory 'cold laser', finding that it caused increased tumour growth in a mouse model of skin cancer.

19 Nov 2009

Adamas Pharmaceuticals expands its Phase 2 TCAD therapy study for influenza A

Adamas Pharmaceuticals, Inc., a privately held company, announced today that it has expanded its Phase 2 clinical study of a proprietary investigational triple-combination antiviral drug therapy for influenza to include centers in the United States, Canada and Europe. The study, which was initiated in August 2009 in the Southern Hemisphere, is designed to investigate Adamas' triple combination antiviral drug (TCAD) therapy as a treatment for influenza A, including novel influenza A/H1N1, the cause of the current flu pandemic.

19 Nov 2009

SinoFresh Nasal Spray effective against 'swine flu' in animal study

SinoFresh Healthcare Products, Inc. announced today the successful results of its initial pilot animal study testing the efficacy of the SinoFresh Nasal Spray product when used on animals infected with the H1N1 virus. The study data suggests that treatment with SinoFresh allowed the infected animals to recover more rapidly from H1N1 infection than did untreated animals. In addition, pre-treatment with SinoFresh Nasal Spray decreased the severity and/or incidence of infection.

19 Nov 2009

DxNA announces successfull evaluation of its GeneSTAT PCR system

DxNA, a molecular diagnostics company headquartered in St. George, Utah, announced today that the DxNA GeneSTAT PCR system has successfully completed evaluation studies under the direction of a California laboratory supported by the Joint FAO/IAEA Programme in Food and Agriculture.

19 Nov 2009

First comprehensive, international baseline evidence about pandemics published

Public health officials walking a tightrope between massive demand for vaccines and intense public scrutiny of side effects now have a new standard for evaluating the safety of their vaccination programs.

19 Nov 2009

Exaggerated responses of immune system explain elders’ susceptibility to viral infections

Researchers at Yale School of Medicine have found that exaggerated responses of the immune system explain why the elderly succumb to viral infections more readily than younger people. Published in the November 19 Cell Host & Microbe, the study bucks the general belief that declining immune responses are to blame for susceptibility to viral infections.

19 Nov 2009